Generic placeholder image

Anti-Cancer Agents in Medicinal Chemistry

Author(s): Zhe Zheng, Guorong Yan, Ningyuan Xi, Xiaoxiang Xu, Qingyu Zeng, Yuhao Wu, Ying Zheng*, Guolong Zhang* and Xiuli Wang*

DOI: 10.2174/1871520623666230413130417

DownloadDownload PDF Flyer Cite As
Triptolide Induces Apoptosis and Autophagy in Cutaneous Squamous Cell Carcinoma via Akt/mTOR Pathway

Page: [1596 - 1604] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Background: Tripterygium wilfordii Hook F provided the source of the first diterpenoid triepoxide lactone, Triptolide, identified as the primary constituent causing the anticancer activity. So far, it has not been reported whether triptolide has a therapeutic effect on cutaneous squamous cell carcinoma (cSCC).

Objective: This study investigates the triptolide's therapeutic impact on cSCC both in vitro and in vivo and investigates the triptolide's potential involvement in signaling pathways.

Methods: The CCK-8 assays, wound healing assays, and colony formation assays were used to assess the effects of triptolide on the proliferation and migration of cSCC cells. The alteration in gene expression following triptolide treatment was shown by RNA sequencing. Flow cytometry was then applied to evaluate cell apoptosis. Western blot was used to find the associated proteins' expressions. The effectiveness of triptolide was then evaluated in vivo using a xenograft model, and histological staining was employed to determine the visceral toxicity.

Results: Triptolide greatly reduces the migratory and proliferative capacity of cSCC cells. Triptolide dramatically decreased cell viability and migration in the A431 and SCL-1 cells compared to the control group, according to the CCK8 assay, wound healing assay, and colony formation assay. Flow cytometry demonstrated that treatment with 10- 40 nM triptolide increased apoptosis in a concentration-dependent manner, with a statistically significant difference. Furthermore, mice given triptolide had smaller tumor sizes than those in the control group. Triptolide treatment drastically altered the expression of autophagic and apoptotic proteins. The considerable reduction in the proteins Akt and mTOR levels further illustrated the critical function of triptolide in cSCC.

Conclusion: Triptolide caused cSCC cells to engage in autophagy and apoptosis by inhibiting the Akt/mTOR signaling pathways. Triptolide may be a possible antitumor agent for the treatment of cSCC.

Graphical Abstract

[1]
Waldman, A.; Schmults, C. Cutaneous squamous cell carcinoma. Hematol. Oncol. Clin. North Am., 2019, 33(1), 1-12.
[http://dx.doi.org/10.1016/j.hoc.2018.08.001] [PMID: 30497667]
[2]
Que, S.K.T.; Zwald, F.O.; Schmults, C.D. Cutaneous squamous cell carcinoma. J. Am. Acad. Dermatol., 2018, 78(2), 237-247.
[http://dx.doi.org/10.1016/j.jaad.2017.08.059] [PMID: 29332704]
[3]
Chang, D.; Shain, A.H. The landscape of driver mutations in cutaneous squamous cell carcinoma. NPJ Genom. Med., 2021, 6(1), 61.
[http://dx.doi.org/10.1038/s41525-021-00226-4] [PMID: 34272401]
[4]
Fan, X.; Niu, X.; Wu, Z.; Yao, L.; Chen, S.; Wan, W.; Huang, B.; Qi, R.Q.; Zhang, T. Computer image analysis reveals C-Myc as a potential biomarker for discriminating between keratoacanthoma and cutaneous squamous cell carcinoma. BioMed Res. Int., 2022, 2022, 1-17.
[http://dx.doi.org/10.1155/2022/3168503] [PMID: 36051475]
[5]
Chen, Y.T.; Hsieh, M.J.; Chen, P.N.; Weng, C.J.; Yang, S.F.; Lin, C.W. Erianin induces apoptosis and autophagy in oral squamous cell carcinoma cells. Am. J. Chin. Med., 2020, 48(1), 183-200.
[http://dx.doi.org/10.1142/S0192415X2050010X] [PMID: 31903779]
[6]
Corchado-Cobos, R.; García-Sancha, N.; González-Sarmiento, R.; Pérez-Losada, J.; Cañueto, J. Cutaneous squamous cell carcinoma: From biology to therapy. Int. J. Mol. Sci., 2020, 21(8), 2956.
[http://dx.doi.org/10.3390/ijms21082956] [PMID: 32331425]
[7]
Stratigos, A.J.; Garbe, C.; Dessinioti, C.; Lebbe, C.; Bataille, V.; Bastholt, L.; Dreno, B.; Concetta, F.M.; Forsea, A.M.; Frenard, C.; Harwood, C.A.; Hauschild, A.; Hoeller, C.; Kandolf-Sekulovic, L.; Kaufmann, R.; Kelleners-Smeets, N.W.J.; Malvehy, J.; del Marmol, V.; Middleton, M.R.; Moreno-Ramirez, D.; Pellecani, G.; Peris, K.; Saiag, P.; van den Beuken-van, E.M.H.J.; Vieira, R.; Zalaudek, I.; Eggermont, A.M.M.; Grob, J.J. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment. Eur. J. Cancer, 2020, 128, 83-102.
[http://dx.doi.org/10.1016/j.ejca.2020.01.008] [PMID: 32113942]
[8]
Wang, Y.; Huang, L.; Tang, X.; Zhang, H. Retrospect and prospect of active principles from Chinese herbs in the treatment of dementia. Acta Pharmacol. Sin., 2010, 31(6), 649-664.
[http://dx.doi.org/10.1038/aps.2010.46] [PMID: 20523337]
[9]
Li, X.J.; Jiang, Z.Z.; Zhang, L. Triptolide: Progress on research in pharmacodynamics and toxicology. J. Ethnopharmacol., 2014, 155(1), 67-79.
[http://dx.doi.org/10.1016/j.jep.2014.06.006] [PMID: 24933225]
[10]
Law, S.K.Y.; Simmons, M.P.; Techen, N.; Khan, I.A.; He, M.F.; Shaw, P.C.; But, P.P.H. Molecular analyses of the Chinese herb Leigongteng (Tripterygium wilfordii Hook.f.). Phytochemistry, 2011, 72(1), 21-26.
[http://dx.doi.org/10.1016/j.phytochem.2010.10.015] [PMID: 21094504]
[11]
Gao, J.; Zhang, Y.; Liu, X.; Wu, X.; Huang, L.; Gao, W. Triptolide: Pharmacological spectrum, biosynthesis, chemical synthesis and derivatives. Theranostics, 2021, 11(15), 7199-7221.
[http://dx.doi.org/10.7150/thno.57745] [PMID: 34158845]
[12]
Liu, X.; Zhao, P.; Wang, X.; Wang, L.; Zhu, Y.; Gao, W. Triptolide induces glioma cell autophagy and apoptosis via upregulating the ROS/JNK and downregulating the Akt/mTOR signaling pathways. Front. Oncol., 2019, 9, 387.
[http://dx.doi.org/10.3389/fonc.2019.00387] [PMID: 31157167]
[13]
Chen, J.; Qiao, Y.; Tang, B.; Chen, G.; Liu, X.; Yang, B.; Wei, J.; Zhang, X.; Cheng, X.; Du, P.; Jiang, W.; Hu, Q.; Hua, Z.C. Modulation of Salmonella tumor-colonization and intratumoral anti-angiogenesis by triptolide and its mechanism. Theranostics, 2017, 7(8), 2250-2260.
[http://dx.doi.org/10.7150/thno.18816] [PMID: 28740548]
[14]
Ziaei, S.; Halaby, R. Immunosuppressive, anti-inflammatory and anti-cancer properties of triptolide: A mini review. Avicenna J. Phytomed., 2016, 6(2), 149-164.
[PMID: 27222828]
[15]
Qiu, D.; Kao, P.N. Immunosuppressive and anti-inflammatory mechanisms of triptolide, the principal active diterpenoid from the Chinese medicinal herb Tripterygium wilfordii Hook. f. Drugs R D., 2003, 4(1), 1-18.
[http://dx.doi.org/10.2165/00126839-200304010-00001] [PMID: 12568630]
[16]
Jiang, X.; Cao, G.; Gao, G.; Wang, W.; Zhao, J.; Gao, C. Triptolide decreases tumor‐associated macrophages infiltration and M2 polarization to remodel colon cancer immune microenvironment via inhibiting tumor‐derived CXCL12. J. Cell. Physiol., 2021, 236(1), 193-204.
[http://dx.doi.org/10.1002/jcp.29833] [PMID: 32495392]
[17]
Sui, B.; Cheng, C.; Shi, S.; Wang, M.; Xu, P. Esterase‐activatable and glutathione‐responsive triptolide nano‐prodrug for the eradication of pancreatic cancer. Adv. NanoBiomed Res., 2021, 1(11), 2100040.
[http://dx.doi.org/10.1002/anbr.202100040] [PMID: 34870282]
[18]
Cai, J.; Yi, M.; Tan, Y.; Li, X.; Li, G.; Zeng, Z.; Xiong, W.; Xiang, B. Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ. J. Exp. Clin. Cancer Res., 2021, 40(1), 190.
[http://dx.doi.org/10.1186/s13046-021-01995-7] [PMID: 34108030]
[19]
Qin, G.; Li, P.; Xue, Z. Triptolide induces protective autophagy and apoptosis in human cervical cancer cells by downregulating Akt/mTOR activation. Oncol. Lett., 2018, 16(3), 3929-3934.
[http://dx.doi.org/10.3892/ol.2018.9074] [PMID: 30128010]
[20]
Mizushima, N.; Levine, B. Autophagy in human diseases. N. Engl. J. Med., 2020, 383(16), 1564-1576.
[http://dx.doi.org/10.1056/NEJMra2022774] [PMID: 33053285]
[21]
Zhou, J.; Jiang, Y.; Chen, H.; Wu, Y.; Zhang, L. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway. Cell Prolif., 2020, 53(2), e12739.
[http://dx.doi.org/10.1111/cpr.12739] [PMID: 31820522]
[22]
Feng, F.B.; Qiu, H.Y. RETRACTED: Effects of artesunate on chondrocyte proliferation, apoptosis and autophagy through the PI3K/AKT/mTOR signaling pathway in rat models with rheumatoid arthritis. Biomed. Pharmacother., 2018, 102, 1209-1220.
[http://dx.doi.org/10.1016/j.biopha.2018.03.142] [PMID: 29710540]
[23]
Rong, L.; Li, Z.; Leng, X.; Li, H.; Ma, Y.; Chen, Y.; Song, F. Salidroside induces apoptosis and protective autophagy in human gastric cancer AGS cells through the PI3K/Akt/mTOR pathway. Biomed. Pharmacother., 2020, 122, 109726.
[http://dx.doi.org/10.1016/j.biopha.2019.109726] [PMID: 31918283]
[24]
Pertea, M.; Kim, D.; Pertea, G.M.; Leek, J.T.; Salzberg, S.L. Transcript-level expression analysis of RNA-seq experiments with HISAT, StringTie and Ballgown. Nat. Protoc., 2016, 11(9), 1650-1667.
[http://dx.doi.org/10.1038/nprot.2016.095] [PMID: 27560171]
[25]
Anders, S.; Pyl, P.T.; Huber, W. HTSeq-A Python framework to work with high-throughput sequencing data. Bioinformatics, 2015, 31(2), 166-169.
[http://dx.doi.org/10.1093/bioinformatics/btu638] [PMID: 25260700]
[26]
Le, F.; Yang, L.; Han, Y.; Zhong, Y.; Zhan, F.; Feng, Y.; Hu, H.; Chen, T.; Tan, B. TPL inhibits the invasion and migration of drug-resistant ovarian cancer by targeting the PI3K/AKT/NF-κB-signaling pathway to inhibit the polarization of M2 TAMs. Front. Oncol., 2021, 11, 704001.
[http://dx.doi.org/10.3389/fonc.2021.704001] [PMID: 34381726]
[27]
Zhong, Y.; Le, F.; Cheng, J.; Luo, C.; Zhang, X.; Wu, X.; Xu, F.; Zuo, Q.; Tan, B. Triptolide inhibits JAK2/STAT3 signaling and induces lethal autophagy through ROS generation in cisplatin resistant SKOV3/DDP ovarian cancer cells. Oncol. Rep., 2021, 45(5), 69.
[http://dx.doi.org/10.3892/or.2021.8020] [PMID: 33760192]
[28]
Fusté, N.P.; Fernández-Hernández, R.; Cemeli, T.; Mirantes, C.; Pedraza, N.; Rafel, M.; Torres-Rosell, J.; Colomina, N.; Ferrezuelo, F.; Dolcet, X.; Garí, E. Cytoplasmic cyclin D1 regulates cell invasion and metastasis through the phosphorylation of paxillin. Nat. Commun., 2016, 7(1), 11581.
[http://dx.doi.org/10.1038/ncomms11581] [PMID: 27181366]
[29]
Kuzmanov, A.; Johansen, P.; Hofbauer, G. FBXO25 promotes cutaneous squamous cell carcinoma growth and metastasis through cyclin D1. J. Invest. Dermatol., 2020, 140(12), 2496-2504.
[http://dx.doi.org/10.1016/j.jid.2020.04.003] [PMID: 32335130]
[30]
Shen, Y.; Xu, J.; Jin, J.; Tang, H.; Liang, J. Cyclin D1 expression in Bowen’s disease and cutaneous squamous cell carcinoma. Mol. Clin. Oncol., 2014, 2(4), 545-548.
[http://dx.doi.org/10.3892/mco.2014.273] [PMID: 24940492]
[31]
Spitz, A.Z.; Gavathiotis, E. Physiological and pharmacological modulation of BAX. Trends Pharmacol. Sci., 2022, 43(3), 206-220.
[http://dx.doi.org/10.1016/j.tips.2021.11.001] [PMID: 34848097]
[32]
Jensen, K. WuWong, D.J.; Wong, S.; Matsuyama, M.; Matsuyama, S. Pharmacological inhibition of Bax-induced cell death: Bax-inhibiting peptides and small compounds inhibiting Bax. Exp. Biol. Med., 2019, 244(8), 621-629.
[http://dx.doi.org/10.1177/1535370219833624] [PMID: 30836793]
[33]
Jiang, X.; Jiang, H.; Shen, Z.; Wang, X. Activation of mitochondrial protease OMA1 by Bax and Bak promotes cytochrome c release during apoptosis. Proc. Natl. Acad. Sci., 2014, 111(41), 14782-14787.
[http://dx.doi.org/10.1073/pnas.1417253111] [PMID: 25275009]
[34]
Yélamos, J.; Moreno-Lama, L.; Jimeno, J.; Ali, S.O. Immunomodulatory roles of PARP-1 and PARP-2: Impact on PARP-Centered cancer therapies. Cancers, 2020, 12(2), 392.
[http://dx.doi.org/10.3390/cancers12020392] [PMID: 32046278]
[35]
Curtin, N.J.; Szabo, C. Poly(ADP-ribose) polymerase inhibition: Past, present and future. Nat. Rev. Drug Discov., 2020, 19(10), 711-736.
[http://dx.doi.org/10.1038/s41573-020-0076-6] [PMID: 32884152]
[36]
Zhang, L.T.; Ke, L.X.; Wu, X.Y.; Tian, H.T.; Deng, H.Z.; Xu, L.Y.; Li, E.M.; Long, L. TRIP13 induces nedaplatin resistance in esophageal squamous cell carcinoma by enhancing repair of DNA damage and inhibiting apoptosis. BioMed Res. Int., 2022, 2022, 1-16.
[http://dx.doi.org/10.1155/2022/7295458] [PMID: 35601150]
[37]
Noel, P.; Von Hoff, D.D.; Saluja, A.K.; Velagapudi, M.; Borazanci, E.; Han, H. Triptolide and its derivatives as cancer therapies. Trends Pharmacol. Sci., 2019, 40(5), 327-341.
[http://dx.doi.org/10.1016/j.tips.2019.03.002] [PMID: 30975442]